HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01696929

Tocilizumab Added to Antipsychotics: Safety Study in Schizophrenia

About this titleRead the official source — NCT01696929

This study assessed thinking abilities.

Medication studyAges 18–50United States
The study in practice

Understand this study

What did researchers investigate?

This study assessed thinking abilities.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
AugustaSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2012
Recruitment status
Completed
Enrollment listed in the registry
8
Sponsor
Brian Miller
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT01696929
Official title
Show the full official title

An Open-Label Trial of Tocilizumab in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Augusta

FAQ

Questions about this study

What did researchers investigate?

This study assessed thinking abilities.

Who is behind this study?

The study sponsor is Brian Miller.

Did this study involve medication?

Yes. The study involved medication, including Tocilizumab.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies